Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Orelabrutinib Could be ‘Preferred’ BTK Inhibitor for MCL

Publish date:: December 12, 2019

Key clinical point: Orelabrutinib, a novel Bruton tyrosine kinase inhibitor, appears safe and effective in patients with relapsed or refractory mantle cell lymphoma.

Major finding: Orelabrutinib produced an overall response rate of 86% and a 12-month progression-free survival rate of 64%.

Study details: A phase 2 trial of 106 patients with relapsed/refractory mantle cell lymphoma.

Disclosures: The study was sponsored by InnoCare Pharma. Dr. Deng reported having no conflicts of interest.

Citation:

Deng L et al. ASH 2019, Abstract 755.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,